Last reviewed · How we verify

NCT05365438

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Recruiting now Phase 4 Last updated 1 May 2024
What this trial tests

Phase 4 trial testing Omega 3-Atorvastatin in Dyslipidemias in 105 participants. Currently enrolling.

Timeline
1 October 2022
Primary endpoint
31 December 2025
31 December 2026

Quick facts

Lead sponsorSeoul National University Bundang Hospital
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment105
Start date1 October 2022
Primary completion31 December 2025
Estimated completion31 December 2026
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Bundang Hospital

Who can join

Adults 20 to 80, any sex, with Dyslipidemias or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Relationship between Polyunsaturated Fatty Acid Metabolism and Atherosclerosis.
    Liu Q, Liu Z, Wu D, Wang S. · · 2024 · cited 2× · PMID 39076540 · DOI 10.31083/j.rcm2504142

Verify or expand the search:

Other recruiting trials for Dyslipidemias

Currently open trials in the same condition.

Other Seoul National University Bundang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05365438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing